

Data Sharing Statement

Rubino. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. *JAMA*. Published January 11, 2022. doi:10.1001/jama.2021.23619

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: Data will be shared with bona fide researchers who submit a research proposal approved by the independent review board. Individual patient data will be shared in data sets in a de-identified and anonymized format. Data will be made available after research completion and approval of the product and product use in the EU and the USA. Information about data access request proposals can be found at novonordisk-trials.com.

When available: beginning date: 09-21-2031

Supporting Documents

Document types: None

Additional Information

Who can access the data: Data will be shared with bona fide researchers who submit a research proposal approved by the independent review board.

Types of analyses: For use as approved by the Independent Review Board according to the IRB Charter (see novonordisk-trials.com).

Mechanisms of data availability: Individual participant data will be shared in trial data sets in a de-identified/anonymised format using a specialised SAS data platform, following approval of a research proposal.